Results of the QUALIOR study demonstrated the effectiveness of a SPEP in mitigating the fatigue caused by oral targeted therapies in patients with metastatic cancer.

Investigators examined the relationship between early-onset keratinocyte carcinoma and the risk for other early-onset primary cancers.

Investigators evaluated dual immune checkpoint inhibitors for safety and efficacy in patients with brain metastases from rare cancers.

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.

Researchers sought to compare the safety and efficacy of pirtobrutinib monotherapy vs bendamustine plus rituximab among treatment-naïve patients with CLL/SLL.

PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.